Solid Biosciences Inc.
Solid Biosciences Inc. is a U.S.-based biopharmaceutical company focused on developing gene therapies and related technologies for rare neuromuscular and cardiac diseases. Its pipeline includes candidates such as SGT-003, SGT-212, SGT-501, and SGT-002, supported by preclinical, clinical, manufacturing, and regulatory activities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of gene therapy candidates aimed at Duchenne muscular dystrophy.
Programs targeting CPVT and other inherited cardiomyopathies.
Discovery, laboratory testing, and clinical trial execution for pipeline candidates.
Third-party manufacturing, process scale-up, and drug product supply for studies.
Supporting technologies used to advance research and development programs.
Customers
Solid Biosciences primarily serves patients through the development of therapies for rare genetic diseases, with eventual commercialization aimed at specialty prescribers and treatment centers. In the development stage, its direct counterparties are regulators, clinical investigators, CROs, CDMOs, and potential collaboration partners rather than traditional commercial customers. Any future buyers of approved products would likely be hospitals, specialty clinics, and payers covering high-cost rare-disease therapies.
Patients with Duchenne muscular dystrophy, CPVT, and other inherited disorders targeted by the pipeline.
Neuromuscular and cardiac specialists who would administer or refer patients for approved therapies.
CROs, investigators, and trial sites that conduct preclinical and clinical studies for the company.
Insurers and health systems that would reimburse future approved gene therapies.
Licensing and collaboration partners that may fund or support development and commercialization.
Strategy
The company’s strategy is to advance its gene therapy pipeline through research, clinical trials, and regulatory interactions while building the manufacturing and quality infrastructure needed for later commercialization. It also seeks to expand its portfolio through additional candidates, technologies, collaborations, and in-licensing opportunities.
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
Gene therapies require reliable cGMP manufacturing and scalable supply for trials and launch.
Broader programs can diversify scientific risk and create partnering opportunities.
Approved gene therapies require sales, marketing, distribution, and market-access capabilities.
Geography
Solid Biosciences is headquartered in the United States and conducts most of its development, regulatory, and corporate activities from there. Its operating model depends on a network of third-party manufacturers and research partners, which may be located outside the U.S. as programs advance. Geography matters mainly through U.S. FDA oversight, access to clinical trial sites, and supply-chain dependence on specialized manufacturing capacity.
Risks
Solid Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and the possibility that its candidates never reach approval or commercialization. It also depends heavily on third-party manufacturers and external funding, so supply disruptions or capital shortfalls could materially slow development.
- Clinical development failureImpact: CriticalLikelihood: Medium
Pipeline value depends on successful trial results and acceptable safety/efficacy.
Exposure - Regulatory delay or rejectionImpact: HighLikelihood: High
Gene therapies require extensive FDA review and may need extra studies or holds lifted.
Exposure: Marketing approvals and clinical trial authorizations
- Financing riskImpact: HighLikelihood: High
The business expects continued losses and may need additional capital to fund operations.
Exposure - Manufacturing and quality riskImpact: HighLikelihood: Medium
The company relies on third-party manufacturers for cGMP supply and scale-up.
Exposure: CDMO production of clinical and future commercial material
- Competitive pressureImpact: MediumLikelihood: Medium
Larger biopharma and other gene therapy developers may reach market first or with better data.
Exposure
Accounting
Judgemental itemsTrial, CRO, and CDMO costs are recognized based on estimates before invoices are received.
Impact: Can shift quarterly operating expense timing
Personnel costs include stock-based awards across R&D and G&A functions.
Impact: Affects reported operating loss without immediate cash outflow
Certain financing instruments may be marked to fair value each period.
Impact: Can add volatility to other income/expense
Third-party trial and cGMP manufacturing costs depend on activity timing and estimates.
Impact: Can materially affect period-to-period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Forte Biosciences, Inc.
Pharmaceutical Preparations
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Solid Power, Inc.
SLDP · Miscellaneous Electrical Machinery, Equipment & Supplies
Last updated: 24/09/2026